They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research. Chapters Cancer research advances - 1:14 Cigall's work in epigenetics - 4:33 Dana-Farber's future new hospital - 9:29 AI centered approaches - 14:15 Looking ahead - 16:51

She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its lead SMARCA2 program (partnered with Lilly), and discusses what she would like to see out of future phase 1 data.

Cigall Kadoch, associate professor and HHMI Investigator, Dana-Farber Cancer Institute and Harvard Medical School, and scientific founder of Foghorn Therapeutics (NASDAQ: FHTX), interviews Rick Young, professor of biology at MIT and member of the Whitehead Institute about the latest research and knowledge of how transcriptional regulation can be harnessed and targeted in drug development. The Experts Cigall Kadoch, Ph.D., is an academic investigator as well as entrepreneur in